Die
OrbusNeich Medical Inc. und die Boston Scientific Corporation (NYSE:
BSX) haben heute alle Stent bezogenen Rechtsstreitigkeiten beigelegt.
Die Übereinkunft klärt die Angelegenheiten beider Parteien in
Deutschland, den Niederlanden, Irland, dem Vereinigten Königreich und
in den Vereinigten Staaten. Die Einigung, welche eine Einmalzahlung
von Boston Scientific an OrbusNeich beinhaltet, regelt alle Stent
bezogenen Kontroversen zwischen den Firmen und enthält keine
zukünftigen finanziellen Verpflichtungen.
About OrbusNeich
OrbusNeich is a global company that designs, develops,
manufactures and markets innovative medical devices for the treatment
of vascular diseases. Current products are the world's first dual
therapy stent, the COMBO Dual Therapy Stent, and the world's first
pro-healing stent, the Genous[TM] Stent. Other products include
stents and balloons marketed under the names of Azule[TM], R stent,
Scoreflex[TM], Sapphire[TM], Sapphire II and Sapphire NC. OrbusNeich
is headquartered in Hong Kong and has operations in Shenzhen, China;
Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan.
OrbusNeich supplies medical devices to interventional cardiologists
in more than 60 countries. For more information, visit
www.OrbusNeich.com.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
solutions that improve the health of patients around the world. As a
global medical technology leader for more than 30 years, we advance
science for life by providing a broad range of high performance
solutions that address unmet patient needs and reduce the cost of
healthcare. For more information, visit www.bostonscientific.com and
connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Forward-looking statements
may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and
estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding regulatory approvals, clinical trials, product performance
and impact, and competitive offerings. If our underlying assumptions
turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the
expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual
results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that
may affect our future operations, see Part I, Item 1A - Risk Factors
in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II,
Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have
filed or will file hereafter. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statements to reflect any change in our expectations or in events,
conditions or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ
from those contained in the forward-looking statements. This
cautionary statement is applicable to all forward-looking statements
contained in this document.
Pressekontakt:
Géraldine Varoqui
Media Relations Europe
Boston Scientific International
+49 2102 489461 (office)
varoquig@bsci.com
Michael Campbell
508-650-8023 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
OrbusNeich Medical:
Jamie Moser / Bryan Darrow
Joele Frank, Wilkinson Brimmer Katcher
+1 212-355-4449
